CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Dravet syndrome is a severe infantile-onset epileptic encephalopathy which begins with febrile seizures and is caused by heterozygous loss-of-function mutations of the voltage-gated sodium channel gene SCN1A. We designed a CRISPR-based gene therapy for Scn1a-haplodeficient mice using multiple guide RNAs (gRNAs) in the promoter regions together with the nuclease-deficient Cas9 fused to transcription activators (dCas9-VPR) to trigger the transcription of SCN1A or Scn1a in vitro. We tested the effect of this strategy in vivo using an adeno-associated virus (AAV) mediated system targeting inhibitory neurons and investigating febrile seizures and behavioral parameters. In both the human and mouse genes multiple guide RNAs (gRNAs) in the upstream, rather than downstream, promoter region showed high and synergistic activities to increase the transcription of SCN1A or Scn1a in cultured cells. Intravenous injections of AAV particles containing the optimal combination of 4 gRNAs into transgenic mice with Scn1a-haplodeficiency and inhibitory neuron-specific expression of dCas9-VPR at four weeks of age increased Nav1.1 expression in parvalbumin-positive GABAergic neurons, ameliorated their febrile seizures and improved their behavioral impairments. Although the usage of transgenic mice and rather modest improvements in seizures and abnormal behaviors hamper direct clinical application, our results indicate that the upregulation of Scn1a expression in the inhibitory neurons can significantly improve the phenotypes, even when applied after the juvenile stages. Our findings also suggest that the decrease in Nav1.1 is directly involved in the symptoms seen in adults with Dravet syndrome and open a way to improve this condition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 3×
“More potent second-generation transcriptional activators have been developed, such as Suntag in which the dCas9 with a repeating peptide array recruits multiple copies of antibody-fused VP64 (Tanenbaum et al., 2014), SAM in which the loops of guide RNA attracts multiple additional transcription factors MS2-p65-HSF1 (K…”
BackgroundResultCRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Highly efficient Cas9-mediated transcriptional programming
Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., P R Iyer, E., Lin, S., Kiani, S., Guzman, C. D., Wiegand, D. J., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3312 · Cited by 1,622
Chan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S. K., Deverman, B. E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4593 · Cited by 1,578
RNA-guided gene activation by CRISPR-Cas9-based transcription factors
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2600 · Cited by 1,328 · cited 2×
“Activities of the first generation dCas9 transcriptional activators, such as dCas9-VP64 or -VP160 (Gilbert et al., 2013; Cheng et al., 2013; Maeder et al., 2013; Perez-Pinera et al., 2013) had a low efficiency.”
BackgroundYu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006) · Nature Neuroscience · doi:10.1038/nn1754 · Cited by 1,173
Efficient in vivo manipulation of mouse genomic sequences at the zygote stage.
Lakso, M., Pichel, J. G., Gorman, J. R., Sauer, B., Okamoto, Y., Lee, E., Alt, F. W., & Westphal, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5860 · Cited by 1,125 · cited 6×
“To evaluate the Cre-dependent dCas9-VPR expression in the mice, we generated a GABAergic neuron specific and constitutive dCas9-VPR expressing mouse line by crossing the floxed-dCas9-VPR mouse with a Vgat-Cre (Ogiwara et al., 2013) and EIIa-Cre (Lakso et al., 1996) driver mice, respectively (Supplemental Fig.”
BackgroundInfluentialEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Ogiwara, I., Miyamoto, H., Morita, N., Atapour, N., Mazaki, E., Inoue, I., Takeuchi, T., Itohara, S., Yanagawa, Y., Obata, K., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5270-06.2007 · Cited by 879
Self-citationAutistic-like behaviour in Scn1a+/− mice and rescue by enhanced GABA-mediated neurotransmission
Han, S., Tai, C., Westenbroek, R. E., Yu, F. H., Cheah, C. S., Potter, G. B., Rubenstein, J. L., Scheuer, T., de la Iglesia, H. O., & Catterall, W. A. (2012) · Nature · doi:10.1038/nature11356 · Cited by 643 · cited 1×
“ciency in the GABAergic neurons, especially in the parvalbumin-positive (PV+) ones, is the major cause of the epileptic seizures, sudden death, intellectual disability and autistic features of Dravet syndrome (Yu et al., 2006; Ogiwara et al., 2007; Han et al., 2012; Ito et al., 2013; Tatsukawa et al., 2018).”
BackgroundCRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency
Matharu, N., Rattanasopha, S., Tamura, S., Maliskova, L., Wang, Y., Bernard, A., Hardin, A., Eckalbar, W. L., Vaisse, C., & Ahituv, N. (2019) · Science · doi:10.1126/science.aau0629 · Cited by 323
A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing
Edraki, A., Mir, A., Ibraheim, R., Gainetdinov, I., Yoon, Y., Song, C.-Q., Cao, Y., Gallant, J., Xue, W., Rivera-Pérez, J. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.003 · Cited by 265
Favero, M., Sotuyo, N. P., Lopez, E., Kearney, J. A., & Goldberg, E. M. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0193-18.2018 · Cited by 163 · cited 1×
“This is likely due to the recovery of PV-positive inhibitory neurons function observed in adult stage (Favero et al., 2018).”
BackgroundSun, Y., Paşca, S. P., Portmann, T., Goold, C., Worringer, K. A., Guan, W., Chan, K. C., Gai, H., Vogt, D., Chen, Y.-J. J., et al. (2016) · eLife · doi:10.7554/elife.13073 · Cited by 141 · cited 1×
“Other studies also using neuronal differentiation of iPS cells derived from patients of Dravet syndrome have shown that GABAergic neurons had deficient action potential generation and excitability whereas excitatory neurons were not significantly affected (Higurashi et al., 2013; Sun et al., 2016).”
BackgroundYamagata, T., Ogiwara, I., Mazaki, E., Yanagawa, Y., & Yamakawa, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.013 · Cited by 57
Self-citationTatsukawa, T., Ogiwara, I., Mazaki, E., Shimohata, A., & Yamakawa, K. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.009 · Cited by 47
Self-citation
Cited by
Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum
Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A. S., & Benfenati, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00063.2021 · Cited by 196
Tanenhaus, A., Stowe, T., Young, A., McLaughlin, J., Aeran, R., Lin, I. W., Li, J., Hosur, R., Chen, M., Leedy, J., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.037 · Cited by 124
“64,68 However, GABA-selective expression of these described transgenes is required for therapeutic efficacy, and the size of these effector transgenes precludes packaging within a single AAV particle.”
Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies
Guerrini, R., Balestrini, S., Wirrell, E. C., & Walker, M. C. (2021) · Neurology · doi:10.1212/wnl.0000000000012744 · Cited by 108
Kaneko, K., Currin, C. B., Goff, K. M., Wengert, E. R., Somarowthu, A., Vogels, T. P., & Goldberg, E. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110580 · Cited by 72
“This finding also has important implications for emerging efforts to increase expression of SCN1A as a potential therapeutic strategy (Colasante et al., 2019; Han et al., 2020; Yamagata et al., 2020).”
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
“…studies on pharmacological inhibition of mGluR5 in FXS mice have had successes (Richter et al. 2015), clinical trials using negative allosteric modulators have failed to date (Berry-Kravis et al. 2016) possibly due to tolerance being developed, which has been observed in mice (Yan et al. 2005).”
Background
Metadata
- Authors
- Yamagata, T., Raveau, M., Kobayashi, K., Miyamoto, H., Tatsukawa, T., Ogiwara, I., Itohara, S., Hensch, T. K., & Yamakawa, K.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 141
- Pages
- 104954
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W3028545429
- Cited by
- 136
- References
- 18
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.